Tenpoint Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
128
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
16
Tenpoint Therapeutics General Information
Description
Operator of a biotechnology platform intended to restore vision for people with degenerative ocular diseases. The company's platform offers engineered cell-based therapies and in vivo reprogramming and has a focus on developing systems that can be delivered directly to the eye, bypassing the need for systemic administration, enabling healthcare providers to make a significant impact on the lives of patients with eye diseases.
Contact Information
Website
www.tenpointtherapeutics.comCorporate Office
- 25 Independence Boulevard
- Suite 100
- Warren, NJ 07059
- United States
Corporate Office
- 25 Independence Boulevard
- Suite 100
- Warren, NJ 07059
- United States
Tenpoint Therapeutics Timeline
Tenpoint Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 20-Aug-2026 | $20M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series B) | 28-Jan-2026 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A) | 12-Jul-2023 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC | 30-Nov-2020 | $8.45M | $8.45M | Completed | Clinical Trials - Phase 3 | |
| 1. University Spin-Out | 01-Jan-2019 | Completed | Clinical Trials - Phase 3 |
Tenpoint Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary | ||||||||
| Series Seed | 6,400,000 | $0.000127 | $1.27 | $1.27 | 1x | $1.27 | 10.63% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Tenpoint Therapeutics Comparisons
Industry
Financing
Details
Tenpoint Therapeutics Competitors (2)
One of Tenpoint Therapeutics’s 2 competitors is Novaliq, a Venture Capital-Backed company based in Heidelberg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novaliq | Venture Capital-Backed | Heidelberg, Germany | ||||
| Ikarovec | Venture Capital-Backed | Norwich, United Kingdom |
Tenpoint Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tenpoint Therapeutics Patents
Tenpoint Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026099504-A1 | Compositions and methods for enriching photoreceptors | Pending | 11-Nov-2024 | ||
| WO-2025083169-A1 | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders | Inactive | 17-Oct-2023 |
Tenpoint Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tenpoint Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| VISUfarma | Corporation | |||
| EQT | PE/Buyout | Minority | ||
| Hillhouse Investment Group | PE/Buyout | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Wille Finance | Family Office | Minority |
Tenpoint Therapeutics Acquisitions (1)
Tenpoint Therapeutics’s most recent deal was a Merger/Acquisition with Visus Therapeutics. The deal was made on 12-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visus Therapeutics | 12-Dec-2024 | Merger/Acquisition | Drug Discovery |
Tenpoint Therapeutics FAQs
-
When was Tenpoint Therapeutics founded?
Tenpoint Therapeutics was founded in 2019.
-
Where is Tenpoint Therapeutics headquartered?
Tenpoint Therapeutics is headquartered in Warren, NJ.
-
What is the size of Tenpoint Therapeutics?
Tenpoint Therapeutics has 128 total employees.
-
What industry is Tenpoint Therapeutics in?
Tenpoint Therapeutics’s primary industry is Drug Discovery.
-
Is Tenpoint Therapeutics a private or public company?
Tenpoint Therapeutics is a Private company.
-
What is Tenpoint Therapeutics’s current revenue?
The current revenue for Tenpoint Therapeutics is .
-
How much funding has Tenpoint Therapeutics raised over time?
Tenpoint Therapeutics has raised $332M.
-
Who are Tenpoint Therapeutics’s investors?
VISUfarma, EQT, Hillhouse Investment Group, Janus Henderson Investors, and Wille Finance are 5 of 16 investors who have invested in Tenpoint Therapeutics.
-
Who are Tenpoint Therapeutics’s competitors?
Novaliq and Ikarovec are competitors of Tenpoint Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
